Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Duvoglustat - Amicus Therapeutics

Drug Profile

Duvoglustat - Amicus Therapeutics

Alternative Names: 1-deoxynojirimycin hydrochloride; AT-2220; AT2220-ERT combo therapy; AT2220-IV; Duvoglustat HCl; duvoglustat hydrochloride; duvoglustat-ERT combo therapy; HGT-3510

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amicus Therapeutics
  • Class Alkaloids; Imino pyranoses; Pharmacological chaperones; Small molecules
  • Mechanism of Action Alpha-glucosidase stimulants; Protein folding stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glycogen storage disease type II
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Glycogen storage disease type II

Most Recent Events

  • 09 Aug 2015 Clinical development of duvoglustat is ongoing
  • 14 Feb 2013 Amicus Therapeutics plans a repeat-dose trial for Glycogen storage disease type II (IV formulation) in USA
  • 04 Jan 2013 Interim data from a phase II trial in Glycogen storage disease type II (combination with ERT) released by Amicus Therapeutics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top